Letrozol Bluefish

Letrozole, the active ingredient in Letrozol Bluefish, is an aromatase inhibitor presented as an oral tablet for oral administration. It is used in the endocrine therapy of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen‑driven tumor growth and improving clinical outcomes.

GNH USA supplies Letrozol Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable global logistics. Our distribution network ensures timely delivery to both established and emerging markets, supporting consistent patient access to essential oncology therapies.

Letrozole is an aromatase inhibitor indicated for hormone‑driven breast cancer.

- Hormone receptor‑positive breast cancer (postmenopausal): reduces estrogen production to inhibit tumor growth. - Adjuvant therapy for early‑stage disease (postmenopausal): lowers risk of cancer recurrence after surgery. - Metastatic breast cancer (postmenopausal): helps control disease progression by sustaining low estrogen levels. - Neoadjuvant treatment (postmenopausal): shrinks tumor size before surgical resection by suppressing estrogen.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient episodes of warmth, sweating, and reddening of the skin. - Joint and muscle pain: arthralgia and myalgia that may limit mobility. - Fatigue: persistent tiredness not relieved by rest, affecting daily activities. - Nausea: mild to moderate upset stomach, sometimes accompanied by loss of appetite.

Serious or Rare Side Effects: - Deep vein thrombosis: formation of blood clots in deep veins, usually in the legs. - Pulmonary embolism: blockage of lung arteries by a clot, causing sudden shortness of breath. - Severe liver injury: marked elevation of liver enzymes, hepatitis, or liver failure.

When prescribing Letrozole, several safety considerations should be observed to minimize risk.

- Assess bone health: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation. - Monitor lipid profile: check cholesterol levels periodically during therapy. - Check liver function: perform baseline and periodic liver enzyme tests. - Avoid use in pregnancy: contraindicated due to teratogenic risk; ensure effective contraception in women of childbearing potential. - Review drug interactions: assess concomitant medications that may affect estrogen metabolism. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Letrozole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations of Letrozole. - Estrogen‑containing hormone therapy: antagonizes Letrozole’s estrogen‑lowering effect. - Tamoxifen: combined use may increase risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine, fluvoxamine): may increase Letrozole exposure. - Anticoagulants (e.g., warfarin): enhanced anticoagulant effect, monitor INR. - Cholesterol‑lowering agents (e.g., statins): possible additive effect on lipid profile.